PMS-OLMESARTAN TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

OLMESARTAN MEDOXOMIL

متاح من:

PHARMASCIENCE INC

ATC رمز:

C09CA08

INN (الاسم الدولي):

OLMESARTAN MEDOXOMIL

جرعة:

20MG

الشكل الصيدلاني:

TABLET

تركيب:

OLMESARTAN MEDOXOMIL 20MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

30/100/1000

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

ملخص المنتج:

Active ingredient group (AIG) number: 0152496002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2017-05-01

خصائص المنتج

_PMS-OLMESARTAN_
Page
1
of
29
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-OLMESARTAN
Olmesartan Medoxomil Tablets, USP
Tablets, 20 mg and 40 mg Oral
Angiotensin II AT
1
Receptor Blocker
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
SUBMISSION CONTROL NO: 266034
DATE OF INITIAL AUTHORIZATION:
May 1, 2017
DATE OF REVISION
August 12, 2022
_PMS-OLMESARTAN_
Page
2
of
29
RECENT MAJOR LABEL CHANGES
2 Contraindications, Pregnancy and Breastfeeding
7 Warnings and Precautions, 7.1 Special Populations, Pregnant women
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 4
1.
INDICATIONS
..................................................................................................................
4
Pediatrics
.............................................................................................................................
4
Geriatrics
.............................................................................................................................
4
2.
CONTRAINDICATIONS
................................................................................................
4
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................... 5
4.
DOSAGE AND ADMINISTRATION
.............................................................................
5
4.1
Dosing Considerations
..................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................. 6
4.3
Reconstitution
...............................................................................................................
6
4.4
Administration
...............................................................................................................
6
4.5
Missed Dose
..................................................................................................................